# Adjuvant testing pipeline for recombinant SARS-CoV2 vaccines

> **NIH NIH N01** · BOSTON CHILDREN'S HOSPITAL · 2021 · $257,000

## Abstract

To identify the optimal adjuvant for recombinant SARS-CoV2 vaccines for vaccine recipients of different ages, and to identify correlates of protection against SARS-CoV2 infection or disease, experimental SARS-CoV2 vaccines will be formulated with a panel of different vaccine adjuvants and tested side-by-side for immunogenicity and efficacy.

## Key facts

- **NIH application ID:** 10473587
- **Project number:** 75N93019C00044-P00006-9999-2
- **Recipient organization:** BOSTON CHILDREN'S HOSPITAL
- **Principal Investigator:** OFER LEVY
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $257,000
- **Award type:** —
- **Project period:** 2019-09-30 → 2024-09-29

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10473587

## Citation

> US National Institutes of Health, RePORTER application 10473587, Adjuvant testing pipeline for recombinant SARS-CoV2 vaccines (75N93019C00044-P00006-9999-2). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10473587. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*